Ian A Thompson1, Baoying Liu1, H Nida Sen1, Xiadong Jiao2, Robert Katamay1, Zhiyu Li1, Mengjun Hu1, Fielding Hejtmancik2, Robert B Nussenblatt3. 1. Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland. 2. Ophthalmic Genetics and Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda, Maryland. 3. Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: drbob@nei.nih.gov.
Abstract
PURPOSE: To determine whether the complement factor H (CFH) tyrosine 402 histidine (Y402H) variant, recently shown to be associated with age-related macular degeneration (AMD) and multifocal choroiditis, is associated with specific ocular sarcoidosis clinical phenotypes in black and white persons. DESIGN: Case-control study. METHODS: The CFH Y402H polymorphism (rs1061170) was genotyped in 41 subjects with ocular sarcoidosis and 393 control subjects. Allele frequencies in the ocular sarcoidosis cases were compared with controls using chi-square score tests. Genotypic model-based (dominant, recessive, and additive) associations of the rs1061170 allele were tested using multivariate logistic regression. Bayesian information criteria were used to formalize model selection. Genotypes were correlated with disease characteristics and severity of ocular inflammation. RESULTS: The C allele (rs1061170) was found in 35% of controls, but occurred with a significantly higher frequency (48.7%) in ocular sarcoidosis cases (odds ratio, 1.72; 95% confidence interval, 1.09 to 2.78; P = .018). Logistic regression demonstrated an association between rs1061170 and ocular sarcoidosis in 2 of 3 genetic models (additive, P = .0078; recessive, P = .0018). Posterior uveitis and panuveitis were overrepresented significantly in cases with the homozygous variant genotype (CC, 91%; P = .047). The population-attributable risk related to this CFH risk variant was 20%. CONCLUSIONS: The Y402H polymorphism of CFH seems to be associated with ocular sarcoidosis in black and white persons. Carriage of the CFH Y402H polymorphism in both alleles is associated with an increased risk for posterior uveitis and panuveitis presentation. The prognostic importance of this genotype will require prolonged follow-up studies. Published by Elsevier Inc.
PURPOSE: To determine whether the complement factor H (CFH) tyrosine 402 histidine (Y402H) variant, recently shown to be associated with age-related macular degeneration (AMD) and multifocal choroiditis, is associated with specific ocular sarcoidosis clinical phenotypes in black and white persons. DESIGN: Case-control study. METHODS: The CFH Y402H polymorphism (rs1061170) was genotyped in 41 subjects with ocular sarcoidosis and 393 control subjects. Allele frequencies in the ocular sarcoidosis cases were compared with controls using chi-square score tests. Genotypic model-based (dominant, recessive, and additive) associations of the rs1061170 allele were tested using multivariate logistic regression. Bayesian information criteria were used to formalize model selection. Genotypes were correlated with disease characteristics and severity of ocular inflammation. RESULTS: The C allele (rs1061170) was found in 35% of controls, but occurred with a significantly higher frequency (48.7%) in ocular sarcoidosis cases (odds ratio, 1.72; 95% confidence interval, 1.09 to 2.78; P = .018). Logistic regression demonstrated an association between rs1061170 and ocular sarcoidosis in 2 of 3 genetic models (additive, P = .0078; recessive, P = .0018). Posterior uveitis and panuveitis were overrepresented significantly in cases with the homozygous variant genotype (CC, 91%; P = .047). The population-attributable risk related to this CFH risk variant was 20%. CONCLUSIONS: The Y402H polymorphism of CFH seems to be associated with ocular sarcoidosis in black and white persons. Carriage of the CFH Y402H polymorphism in both alleles is associated with an increased risk for posterior uveitis and panuveitis presentation. The prognostic importance of this genotype will require prolonged follow-up studies. Published by Elsevier Inc.
Authors: Riina Oksjoki; Hanna Jarva; Petri T Kovanen; Petri Laine; Seppo Meri; Markku O Pentikäinen Journal: Arterioscler Thromb Vasc Biol Date: 2003-01-23 Impact factor: 8.311
Authors: Yoshihiko Usui; Elizabeth D E Kaiser; Robert F See; Narsing A Rao; Om P Sharma Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2002-10 Impact factor: 0.670
Authors: Jonathan L Haines; Michael A Hauser; Silke Schmidt; William K Scott; Lana M Olson; Paul Gallins; Kylee L Spencer; Shu Ying Kwan; Maher Noureddine; John R Gilbert; Nathalie Schnetz-Boutaud; Anita Agarwal; Eric A Postel; Margaret A Pericak-Vance Journal: Science Date: 2005-03-10 Impact factor: 47.728
Authors: Andreas Jönsen; Sara C Nilsson; Emma Ahlqvist; Elisabet Svenungsson; Iva Gunnarsson; Karin G Eriksson; Anders Bengtsson; Agneta Zickert; Maija-Leena Eloranta; Lennart Truedsson; Lars Rönnblom; Gunnel Nordmark; Gunnar Sturfelt; Anna M Blom Journal: Arthritis Res Ther Date: 2011-12-15 Impact factor: 5.156
Authors: Robert B Nussenblatt; Richard W J Lee; Emily Chew; Lai Wei; Baoying Liu; H Nida Sen; Andrew D Dick; Frederick L Ferris Journal: Am J Ophthalmol Date: 2014-04-04 Impact factor: 5.258
Authors: Lori Garman; Nathan Pezant; Ambra Pastori; Kathryn A Savoy; Chuang Li; Albert M Levin; Michael C Iannuzzi; Benjamin A Rybicki; Indra Adrianto; Courtney G Montgomery Journal: Ocul Immunol Inflamm Date: 2020-03-06 Impact factor: 3.070
Authors: Amy G Hise; Zachary Traylor; Noémi B Hall; Laura J Sutherland; Saidi Dahir; Megan E Ermler; Samuel Muiruri; Eric M Muchiri; James W Kazura; A Desirée LaBeaud; Charles H King; Catherine M Stein Journal: PLoS Negl Trop Dis Date: 2015-03-10
Authors: C A Lareau; C F DeWeese; I Adrianto; C J Lessard; P M Gaffney; M C Iannuzzi; B A Rybicki; A M Levin; C G Montgomery Journal: Genes Immun Date: 2017-03-09 Impact factor: 4.248